Travere Therapeutics is rated Buy, with a DCF-based fair value of ~$81 per share, implying 27% upside. Click here to read ...
Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.
Travere Therapeutics (NASDAQ:TVTX) is pursuing growth through expanded use of FILSPARI in rare kidney diseases while ...
The Nomura Small Cap Core Fund trailed its benchmark in Q2 2026 despite an exceptionally strong rally in small-cap stocks. Read the full analysis for more details.
Operator: Good morning, and welcome to Travere Therapeutics Second Quarter 2026 Financial Results Conference Call. Today's call is being recorded. At this time, I would like to turn the conference ...
Investor's Business Daily on MSN
IBD stock of the day, Travere Therapeutics, tests another breakout. Can the stock get any 'sweeter?'
Travere Therapeutics is Friday's IBD Stock Of The Day. As the Filspari story gets "sweeter," shares are clearing a fresh buy ...
Zacks.com on MSN
Travere (TVTX) Reports Q2 Earnings: What Key Metrics Have to Say
For the quarter ended June 2026, Travere Therapeutics (TVTX) reported revenue of $169.58 million, up 48.2% over the same period last year. EPS came in at -$0.37, compared to -$0.14 in the year-ago ...
Live webcasts of the presentations will be accessible on the Investor page of Travere’s website at ir.travere.com/events-and-presentations. Replays will be ...
Travere Therapeutics, Inc. (Nasdaq: TVTX) today reported its second quarter 2026 financial results and provided a corporate update. “With an exceptional second quarter, Travere has entered a new ...
At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results